But I dont think these supplements are inherently bad. Consumers need to do their research after all, products like these are not regulated by the FDA
This market is for these GLP-1 agonists administered as a single drug or in combination with other receptor agonists, such as insulin
: , , As hopeful as this is, a few big questions remain, especially if we care about equity and not just headlines: - Will oral GLP-1s actually be covered by insurers and employers as long term therapy, instead of short weight loss sprints followed by predictable regain - How will pricing and step edits work when a patient has already been on an injectable for more than a year - Will these trials and future studies meaningfully include the diverse, underrepresented communities that carry a disproportionate burden of obesity, sleep apnea, and cardiometabolic disease : - Set expectations early: discuss obesity as chronic disease, and proactively plan for maintenance before stopping anything
For type 2 diabetes, NICE guidance (NG28) recommends GLP-1 RAs based on individual factors including comorbidities, prior treatments, and HbA1c targets
For example, someone might combine one (or more) weight-loss peptides with one that claims to improve skin elasticity
1501 Westcliff Dr